CClinicalTrials.gg
RecruitingNCT05213676Updated Aug 18, 2026

De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia

A Phase 4 interventional study of Inhaled Nitric Oxide (iNO) use and De-implementation of Inhaled Nitric Oxide (iNO) use in Congenital Diaphragmatic Hernia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 19 sites in United States. Open to participants aged 0 Months to 1 Month. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by The University of Texas Health Science Center, Houston · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
0 Months to 1 Month
Sex
All
01

Study summary

The purpose of this study is to determine if de-implementation of inhaled nitric oxide (iNO) in the post-natal resuscitation/stabilization phase affects the composite outcome of extracorporeal life support (ECLS) use and/or mortality, as well as ECLS use, mortality, and/or oxygenation in congenital diaphragmatic hernia (CDH) newborns and to establish the cost-effectiveness of de-implementing iNO as a therapy in the postnatal resuscitation/stabilization phase of CDH management, which will be assessed as the incremental health system costs (savings) per prevented ECLS use and/or death.

Read the detailed description

In this multi-center study, centers will use iNO per their usual protocol, and centers will then crossover to iNO de-implementation (that is, at the time of crossover, centers will stop using iNO in the initial resuscitation period). A stepped-wedge crossover study design will be used, and the timing of crossover will be cluster randomized at the level of the center.

02

Conditions studied

  • Congenital Diaphragmatic Hernia

Keywords

  • CDH
  • Inhaled Nitric Oxide
  • Pulmonary Hypertension
03

Who can participate

Ages eligible
0 Months to 1 Month
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Postnatal, live born neonates with CDH

    a. Presence of associated or additional anomalies is acceptable for inclusion

  • Bochdalek hernia location (right or left)
  • Diagnosed prior to 1 month of life
  • Born within or transferred to (within 1 week of life) a CDHSG member center participating in the trial

Exclusion criteria

Exclusion Criteria:

  • CDH diagnosis after 1 month of age
  • Morgagni diaphragmatic hernia (central / anterior-medial diaphragmatic defect location)
  • Transferred to a CDH Study Group (CDHSG) member center after 1 week of life
  • Patients without potential access to iNO
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    Inhaled Nitric Oxide (iNO) use

    The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.

    Drug: Inhaled Nitric Oxide (iNO) use

  • Active comparator
    De-implementation of Inhaled Nitric Oxide (iNO) use

    The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).

    Other: De-implementation of Inhaled Nitric Oxide (iNO) use

Interventions

  • DrugInhaled Nitric Oxide (iNO) use

    The center will use iNO per their usual protocol in the initial resuscitation period (defined as birth through stabilization and CDH repair). No center will alter any component of their standard clinical practice guideline or protocol governing CDH care.

  • OtherDe-implementation of Inhaled Nitric Oxide (iNO) use

    The center will stop using iNO in the initial resuscitation period (defined as birth through stabilization and CDH repair).

05

What researchers measure

Primary outcomes

  1. Number of participants who require Extracorporeal Life Support (ECLS) and/or who die prior to discharge

    The primary outcome is the composite outcome of ECLS use and/or mortality.

    Time frame: from birth through hospital discharge (up to 12 months from birth)

Secondary outcomes

  1. Number of participants who require Extracorporeal Life Support (ECLS) prior to discharge

    Time frame: from birth through hospital discharge (up to 12 months from birth)

  2. Number of participants who die prior to discharge

    Time frame: from birth through hospital discharge (up to 12 months from birth)

  3. Change in oxygenation

    For the iNO de-implementation arm, participants will be assessed 1 hour after the time when iNO would have been initiated, per the protocol of the center.

    Time frame: 1 hour after initiation of iNO use

  4. Change in oxygenation

    For the iNO de-implementation arm, participants will be assessed 6 hours after the time when iNO would have been initiated, per the protocol of the center.

    Time frame: 6 hours after initiation of iNO use

  5. Total cost of initial inpatient care from birth through hospital discharge, per center

    Time frame: from birth through hospital discharge (up to 12 months from birth)

06

Study locations

19 of 19 sites recruiting
  • University of Alabama & Children's Hospital of Alabama (UAB-CoA)
    Birmingham, Alabama 35233, United States
    Recruiting
  • University of Arkansas & Arkansas Children's Hospital (UA-ACH)
    Little Rock, Arkansas 72202, United States
    Recruiting
  • University of California-Irvine & Children's Hospital of Orange County (UC-CHOC)
    Irvine, California 92868, United States
    Recruiting
  • University of Southern California & Children's Hospital Los Angeles (USC-CHLA)
    Los Angeles, California 90027, United States
    Recruiting
  • Stanford University & Lucile Packard Children's Hospital (Stanford-LPCH)
    Palo Alto, California 94304, United States
    Recruiting
  • University of California, San Diego & Rady Children's Hospital (UCSD-Rady)
    San Diego, California 92123, United States
    Recruiting
  • University of Colorado & Children's Hospital of Colorado (CU-CHC)
    Aurora, Colorado 80045, United States
    Recruiting
  • Emory University & Children's Healthcare of Atlanta (CHOA)
    Atlanta, Georgia 30322, United States
    Recruiting
  • Indiana University & Riley Children's Hospital (IU-RiCH)
    Indianapolis, Indiana 46202, United States
    Recruiting
  • University of Louisville & Norton Children's Hospital (UL-NCH)
    Louisville, Kentucky 40202, United States
    Recruiting
  • Harvard University & Boston Children's Hospital (Harvard-BCH)
    Boston, Massachusetts 02115, United States
    Recruiting
  • University of Michigan & CS Mott Children's Hospital (UM-CSMott)
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Randall Children's Hospital-Portland (RCH)
    Portland, Oregon 97227, United States
    Recruiting
  • Medical University of South Carolina Children's Health (MUSC)
    Charleston, South Carolina 29425, United States
    Recruiting
  • University of Tennessee & LeBonheur Children's Hospital (UT-LBCH)
    Memphis, Tennessee 38105, United States
    Recruiting
  • Vanderbilt University & Vanderbilt University Medical Center (VUMC)
    Nashville, Tennessee 37232, United States
    Recruiting
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
    Recruiting
  • University of Utah & Primary Children's Hospital (Utah-PCH)
    Salt Lake City, Utah 84108, United States
    Recruiting
  • University of Washington & Seattle Children's Hospital (UW-SCH)
    Seattle, Washington 98105, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05213676
Lead sponsor
The University of Texas Health Science Center, Houston
Collaborators
University of Tennessee & LeBonheur Children's Hospital (UT-LBCH), Children's Hospital of Orange County, Medical University of South Carolina Children's Health (MUSC), University of Michigan & CS Mott Children's Hospital (UM-CSMott), Randall Children's Hospital-Portland (RCH), Stanford University & Lucile Packard Children's Hospital (Stanford-LPCH), Rady Children's Hospital, San Diego, Boston Children's Hospital, Indiana University & Riley Children's Hospital (IU-RiCH), Norton Children's Hospital, University of Utah & Primary Children's Hospital (Utah-PCH), University of Washington & Seattle Children's Hospital (UW-SCH), University of Alabama & Children's Hospital of Alabama (UAB-CoA), University of Arkansas, Vanderbilt University Medical Center, University of Southern California & Children's Hospital Los Angeles (USC-CHLA), Emory University & Children's Healthcare of Atlanta (CHOA), Children's Hospital Colorado
Responsible party
Matthew T Harting (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Jan 28, 2022
Start date
Nov 1, 2025
Primary completion
Oct 31, 2030 (estimated)
Completion
Apr 30, 2031 (estimated)
Last update
Aug 18, 2026

Study contacts

Matthew Harting, MD, MS, FACS
Contact
Matthew.T.Harting@uth.tmc.edu
(713) 500-7398
Ashley Ebanks
Contact
Ashley.Harmon@uth.tmc.edu
(832) 325-7234
Matthew Harting, MD, MS, FACS
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion